Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTögel, Lars-
dc.contributor.authorNightingale, Rebecca-
dc.contributor.authorWu, Rui-
dc.contributor.authorChüeh, Anderly C-
dc.contributor.authorAl-Obaidi, Sheren-
dc.contributor.authorLuk, Ian-
dc.contributor.authorDávalos-Salas, Mercedes-
dc.contributor.authorChionh, Fiona-
dc.contributor.authorMurone, Carmel-
dc.contributor.authorBuchanan, Daniel D-
dc.contributor.authorChatterton, Zac-
dc.contributor.authorSieber, Oliver M-
dc.contributor.authorArango, Diego-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorWilliams, David-
dc.contributor.authorDhillon, Amardeep S-
dc.contributor.authorMariadason, John M-
dc.identifier.citationScientific Reports 2018; 8(1): 1767en
dc.description.abstractThe ERK signalling pathway regulates key cell fate decisions in the intestinal epithelium and is frequently dysregulated in colorectal cancers (CRCs). Variations in the dynamics of ERK activation can induce different biological outcomes and are regulated by multiple mechanisms, including activation of negative feedback loops involving transcriptional induction of dual-specificity phosphatases (DUSPs). We have found that the nuclear ERK-selective phosphatase DUSP5 is downregulated in colorectal tumours and cell lines, as previously observed in gastric and prostate cancer. The DUSP5 promoter is methylated in a subset of CRC cell lines and primary tumours, particularly those with a CpG island methylator phenotype (CIMP). However, this epigenetic change alone could not account for reduced DUSP5 expression in CRC cells. Functionally, DUSP5 depletion failed to alter ERK signalling or proliferation in CRC cell lines, and its transgenic overexpression in the mouse intestine had minimal impact on normal intestinal homeostasis or tumour development. Our results suggest that DUSP5 plays a limited role in regulating ERK signalling associated with the growth of colorectal tumours, but that methylation the DUSP5 gene promoter can serve as an additional means of identifying CIMP-high colorectal cancers.en
dc.titleDUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.en
dc.typeJournal Articleen
dc.identifier.journaltitleScientific Reportsen
dc.identifier.affiliationSystems Biology and Personalised Medicine Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationGroup of Biomedical Research in Digestive Tract Tumours, CIBBIM-Nanomedicine, Vall d'Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spainen
dc.identifier.affiliationColorectal Oncogenomics Group, Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, Melbourne, Australiaen
dc.identifier.affiliationLa Trobe University School of Cancer Medicine, Melbourne, Australiaen
dc.identifier.affiliationLudwig Institute for Cancer Research, Melbourne, Australiaen
dc.type.austinJournal Article-, John M
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en- Newton-John Cancer Research Institute- Oncology- Newton-John Cancer Wellness and Research Centre- Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 16, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.